BioNTech to Report Second Quarter 2024 Financial Results and Corporate Update on August 5, 2024
MAINZ, Germany, July 22, 2024 - BioNTech SE (Nasdaq: BNTX, BioNTech or the Company) has announced that it will be releasing its financial results for the second quarter of 2024 on Monday, August 5, 2024. Alongside the financial report, the Company will be hosting a conference call and webcast at 8:00 a.m. EDT (2:00 p.m. CEST) on the same day. This event is open to investors, financial analysts, and the general public. The purpose of the call and webcast will be to discuss the financial results and provide a corporate update.
This announcement comes on the heels of BioNTech’s recent collaboration with Genmab A/S in the development of Investigational Acasunlimab (DuoBody-PD-L1x4-1BB) for the treatment of metastatic non-small cell lung cancer (mNSCLC). Initial data from the ongoing Phase 2 trial showed promising results, with a 12-month overall survival rate of 69%, a median overall survival of 17.5 months, and an overall response rate of 30% in patients treated with the combination of acasunlimab and pembrolizumab. These findings were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago.
In another significant development, BioNTech and the Coalition for Epidemic Preparedness Innovations (CEPI) have expanded their partnership to strengthen Africa’s mRNA vaccine ecosystem. CEPI has committed up to US $145 million to support BioNTech in establishing mRNA vaccine research and development, as well as clinical and commercial-scale manufacturing capabilities at the Company’s facility in Kigali, Rwanda. These efforts aim to better prepare Africa for potential future epidemic and pandemic threats.
The expansion of BioNTech’s operations in Africa signifies the company’s commitment to global health and its dedication to ensuring equitable access to life-saving vaccines. This strategic partnership with CEPI will contribute to the development of a sustainable and resilient African vaccine ecosystem, ultimately benefiting millions of people across the continent.
In summary, BioNTech’s upcoming financial results announcement and corporate update on August 5, 2024, coupled with its recent advancements in cancer treatment and commitment to Africa’s vaccine ecosystem, cement the Company’s position as a global leader in biotechnology and healthcare.
Comments